What We're Reading: Page 100
Industry reads hand-picked by our editors
Jun 05, 2023
-
The Boston Globe
Biotechs face challenges as the industry’s annual bash returns to Boston
-
CNN
FDA to allow imports of cancer drug from China amid ongoing shortage
-
The Wall Street Journal
Even Mark Cuban Can’t Fix This Broken Drug System
-
Reuters
Musk’s Neuralink valued at about $5 bln despite long road to market
Jun 02, 2023
-
Boston Business Journal
Big Pharma keeps on coming to Boston: ‘That’s where the action is’
-
Bloomberg
FTC Chair Lina Khan Investigation Launched by US House Committee
-
The Washington Post
Biden plans to pick physician Mandy Cohen to lead CDC
-
Science
U.S. study will test whether drug combinations can wipe out tumors
Jun 01, 2023
May 31, 2023
-
Financial Times
Centerview: the Wall St power brokers confronting a rare rupture
-
Bloomberg
Eradicate Breast Cancer? The Hunt for a Vaccine Looks Promising
-
The New York Times
To Prevent Heart Attacks, Doctors Try a New Genetic Test
May 30, 2023
May 26, 2023
-
BioCentury
Default could shutter FDA reviews
-
In The Pipeline
AI and the Hard Stuff
-
Evaluate Vantage
Asco 2023 – Regeneron nips at Bristol’s heels in Lag3
-
CNBC
FDA grants full approval to Pfizer Covid treatment Paxlovid for high-risk adults
May 25, 2023
-
The Economist
Clinical trials are too slow and too costly—here is how to fix them
-
The Washington Post
Medical use of ketamine is surging. So are illicit forms of the drug.
-
CNN
Experimental drugs aim to surpass weight-loss stars like Ozempic and Wegovy
-
PharmaVoice
From FTC to SCOTUS, Amgen’s woes are potential ‘game changers’ for the industry
Previous
